Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

A number of other brokerages have also commented on BHVN. BidaskClub raised shares of Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 28th. Morgan Stanley reaffirmed an “overweight” rating and issued a $38.00 target price (down previously from $47.00) on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, October 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 target price (up previously from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, September 13th. William Blair reaffirmed an “outperform” rating on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, October 3rd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $54.00 target price on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, September 12th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Biohaven Pharmaceutical Holding Co has an average rating of “Buy” and an average price target of $40.80.

Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) traded up 1.65% during mid-day trading on Tuesday, hitting $32.07. 120,644 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $36.15 and a 200 day moving average of $27.93. Biohaven Pharmaceutical Holding Co has a 52 week low of $17.00 and a 52 week high of $39.51. The stock’s market capitalization is $1.15 billion.

COPYRIGHT VIOLATION NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Upgraded to Hold by Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/17/biohaven-pharmaceutical-holding-co-ltd-bhvn-upgraded-to-hold-by-zacks-investment-research.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical Holding Co (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.